Wait, we have a special offer for you! ✋

Get your exclusive discount now

Use FY25SAVE to get flat 20% off on the report No, I'd pay the full price

Terms & Conditions : This coupon is vaild exclusively for Global Market Reports 2025 and can be used Until March 31 , 2025 .

Global Acute Intermittent Porphyria Market Report 2025

Acute Intermittent Porphyria Global Market Report 2025 – By Diagnosis (Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis), By Treatment (Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments), By End-Users (Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers) – Market Size, Trends, And Global Forecast 2025-2034

Acute Intermittent Porphyria Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Acute Intermittent Porphyria Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Acute Intermittent Porphyria Market Definition

Acute intermittent porphyria (AIP) is a rare genetic disorder that affects the production of heme, a vital component of hemoglobin in the blood. AIP is characterized by intermittent attacks of severe abdominal pain, gastrointestinal disturbances, and neurological symptoms, including muscle weakness, seizures, and mental changes such as anxiety, confusion, or hallucinations.

The main acute intermittent porphyria diagnoses include urine tests, blood tests, serum tests, DNA tests, and others. The urine test method involves analyzing a sample of urine to detect elevated levels of porphyrins or their precursors, which are indicators of acute intermittent porphyria (AIP). It offers various types of treatments, such as prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and others, and it is used by hospitals and clinics, ambulatory surgical centers, and research centers.

Acute Intermittent Porphyria Market Segmentation

The acute intermittent porphyriamarket covered in this report is segmented –

1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis

2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments

3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test

2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test

3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test

4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test

5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.

Acute Intermittent Porphyria Market Size and growth rate 2025 to 2029: Graph

Acute Intermittent Porphyria Market Size 2025 And Growth Rate

The acute intermittent porphyria market size has grown strongly in recent years. It will grow from $4.37 billion in 2024 to $4.66 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising healthcare expenditure, growth in biopharmaceuticals market, rising prevalence of genetic disorders, expansion of telemedicine services, and growing focus on early detection.

Acute Intermittent Porphyria Market Growth Forecast

The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $5.96 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing incidence of acute intermittent porphyria, growing awareness of rare diseases, supportive government policies, growing patient advocacy, and expansion of genetic testing services. Major trends in the forecast period include advancements in diagnostic techniques, development of novel therapeutic options, investment in research and development, collaborations between pharma companies, and technological innovations in treatment.

Book your 30 minutes free consultation with our research experts

Contact Us

Acute Intermittent Porphyria Market Driver: Impact Of Rising Metabolic Disorders On The Growth Of The Acute Intermittent Porphyria Market

The prevalence of metabolic disorders is expected to propel the growth of the acute intermittent porphyria market going forward. Metabolic disorders are a group of conditions that occur due to abnormal chemical reactions in the body that disrupt the normal process of metabolism. The prevalence of metabolic disorders is due to genetic factors, lifestyle factors, environmental influences, and increased awareness and diagnosis. The rise in metabolic disorders is encouraging the pharmaceutical industry to invest in treatments for rare and genetic conditions such as acute intermittent porphyria. For instance, in December 2023, according to Cleveland Clinic, a US-based nonprofit academic medical center, inherited metabolic disorders collectively impact approximately 1 in 1,000 to 2,500 births worldwide. Therefore, the prevalence of metabolic disorders is driving the growth of the acute intermittent porphyria market.

Global Acute Intermittent Porphyria Market Major Players

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

Global Acute Intermittent Porphyria Market Trend: Innovations In Acute Intermittent Porphyria Management

Major companies operating in the acute intermittent porphyria market are focused on developing innovative products, such as acute intermittent porphyria management tablets, to serve customers with advanced features better. Acute intermittent porphyria management tablets refer to oral medications used to manage or prevent the symptoms and acute attacks associated with AIP. For instance, in October 2023, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, announced the US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg. Chlorpromazine hydrochloride tablets USP, available in doses of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, are used to manage the symptoms of psychotic disorders and treat schizophrenia. They also help control nausea and vomiting, alleviate restlessness and apprehension before surgery, and serve as an adjunct in treating tetanus. Additionally, these tablets are utilized in the management of acute intermittent porphyria, control manic symptoms of manic-depressive illness, and provide relief from intractable hiccups.

Acute Intermittent Porphyria Market Merger And Acquisition: American Porphyria Foundation Partners With Recordati Rare Diseases To Advance AIP Awareness And Support

In April 2024, the American Porphyria Foundation (APF), a US-based non-profit organization, partnered with Recordati Rare Diseases. Through this partnership, the American Porphyria Foundation (APF) aims to raise awareness of porphyria and enhance public understanding and support for AIP. Recordati Rare Diseases is an Italy-based pharmaceutical company treating acute intermittent porphyria (AIP).

Regional Outlook For The Global Acute Intermittent Porphyria Market

North America was the largest region in the acute intermittent porphyria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute intermittent porphyria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Intermittent Porphyria Market?

The acute intermittent porphyria market consists of revenues earned by entities by providing services such as genetic testing, clinical consultation, treatment planning and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute intermittent porphyria market also includes sales of symptom management products, medical devices, nutritional supplements and emergency kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Acute Intermittent Porphyria Industry?

The acute intermittent porphyria market research report is one of a series of new reports from The Business Research Company that provides acute intermittent porphyria market statistics, including acute intermittent porphyria industry global market size, regional shares, competitors with a acute intermittent porphyria market share, detailed acute intermittent porphyria market segments, market trends and opportunities, and any further data you may need to thrive in the acute intermittent porphyria industry. This acute intermittent porphyria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute Intermittent Porphyria Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $4.66 billion
Revenue Forecast In 2034 $5.96 billion
Growth Rate CAGR of 6.3% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis
2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments
3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers Subsegments: 1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test
2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test
3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test
4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test
5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Acute Intermittent Porphyria Market Characteristics

    3. Acute Intermittent Porphyria Market Trends And Strategies

    4. Acute Intermittent Porphyria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    5. Global Acute Intermittent Porphyria Growth Analysis And Strategic Analysis Framework

    5.1. Global Acute Intermittent Porphyria PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Acute Intermittent Porphyria Market Growth Rate Analysis

    5.4. Global Acute Intermittent Porphyria Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Acute Intermittent Porphyria Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Acute Intermittent Porphyria Total Addressable Market (TAM)

    6. Acute Intermittent Porphyria Market Segmentation

    6.1. Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Urine Test

    Blood Test

    Serum Test

    DNA Test

    Other Diagnosis

    6.2. Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Prophylactic Hematin Infusions

    Gonadotropin-Releasing Hormone Analogues

    Other Treatments

    6.3. Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals and Clinics

    Ambulatory Surgical Centers

    Research Centers

    6.4. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Urine Porphobilinogen (PBG) Test

    Urine Aminolevulinic Acid (ALA) Test

    Urine Color Change Test

    6.5. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Plasma Porphyrin Levels Test

    Blood Aminolevulinic Acid (ALA) Test

    Complete Blood Count (CBC) Test

    6.6. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Serum Porphyrin Levels Test

    Liver Function Test (LFT)

    Serum ALA and PBG Enzyme Test

    6.7. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Genetic Mutation Testing

    Gene Sequencing Test

    6.8. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Stool Test for Porphyrins

    Imaging Tests (CT/MRI Scans for Complications)

    Enzyme Activity Assays

    7. Acute Intermittent Porphyria Market Regional And Country Analysis

    7.1. Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Acute Intermittent Porphyria Market

    8.1. Asia-Pacific Acute Intermittent Porphyria Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Acute Intermittent Porphyria Market

    9.1. China Acute Intermittent Porphyria Market Overview

    9.2. China Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Acute Intermittent Porphyria Market

    10.1. India Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Acute Intermittent Porphyria Market

    11.1. Japan Acute Intermittent Porphyria Market Overview

    11.2. Japan Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Acute Intermittent Porphyria Market

    12.1. Australia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Acute Intermittent Porphyria Market

    13.1. Indonesia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Acute Intermittent Porphyria Market

    14.1. South Korea Acute Intermittent Porphyria Market Overview

    14.2. South Korea Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Acute Intermittent Porphyria Market

    15.1. Western Europe Acute Intermittent Porphyria Market Overview

    15.2. Western Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Acute Intermittent Porphyria Market

    16.1. UK Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Acute Intermittent Porphyria Market

    17.1. Germany Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Acute Intermittent Porphyria Market

    18.1. France Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Acute Intermittent Porphyria Market

    19.1. Italy Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Acute Intermittent Porphyria Market

    20.1. Spain Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Acute Intermittent Porphyria Market

    21.1. Eastern Europe Acute Intermittent Porphyria Market Overview

    21.2. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Acute Intermittent Porphyria Market

    22.1. Russia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Acute Intermittent Porphyria Market

    23.1. North America Acute Intermittent Porphyria Market Overview

    23.2. North America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Acute Intermittent Porphyria Market

    24.1. USA Acute Intermittent Porphyria Market Overview

    24.2. USA Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Acute Intermittent Porphyria Market

    25.1. Canada Acute Intermittent Porphyria Market Overview

    25.2. Canada Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Acute Intermittent Porphyria Market

    26.1. South America Acute Intermittent Porphyria Market Overview

    26.2. South America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Acute Intermittent Porphyria Market

    27.1. Brazil Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Acute Intermittent Porphyria Market

    28.1. Middle East Acute Intermittent Porphyria Market Overview

    28.2. Middle East Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Acute Intermittent Porphyria Market

    29.1. Africa Acute Intermittent Porphyria Market Overview

    29.2. Africa Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Acute Intermittent Porphyria Market Competitive Landscape And Company Profiles

    30.1. Acute Intermittent Porphyria Market Competitive Landscape

    30.2. Acute Intermittent Porphyria Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

    31. Acute Intermittent Porphyria Market Other Major And Innovative Companies

    31.1. Sanofi SA

    31.2. AstraZeneca Plc

    31.3. Novartis AG

    31.4. GlaxoSmithKline Plc

    31.5. Takeda Pharmaceutical Company Limited

    31.6. Eli Lilly and Company

    31.7. Gilead Sciences Inc.

    31.8. Amgen Inc.

    31.9. Novo Nordisk A/S

    31.10. Regeneron Pharmaceuticals Inc.

    31.11. Daiichi Sankyo Company Limited

    31.12. Vertex Pharmaceuticals Inc.

    31.13. Eisai Co. Ltd.

    31.14. Octapharma AG

    31.15. BioMarin Pharmaceutical Inc.

    32. Global Acute Intermittent Porphyria Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Acute Intermittent Porphyria Market

    34. Recent Developments In The Acute Intermittent Porphyria Market

    35. Acute Intermittent Porphyria Market High Potential Countries, Segments and Strategies

    35.1 Acute Intermittent Porphyria Market In 2029 - Countries Offering Most New Opportunities

    35.2 Acute Intermittent Porphyria Market In 2029 - Segments Offering Most New Opportunities

    35.3 Acute Intermittent Porphyria Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Pfizer Inc. Financial Performance
  • Table 80: Johnson & Johnson Financial Performance
  • Table 81: Roche Holding AG Financial Performance
  • Table 82: Merck & Co. Inc. Financial Performance
  • Table 83: AbbVie Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Pfizer Inc. Financial Performance
  • Figure 80: Johnson & Johnson Financial Performance
  • Figure 81: Roche Holding AG Financial Performance
  • Figure 82: Merck & Co. Inc. Financial Performance
  • Figure 83: AbbVie Inc. Financial Performance

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

Global Cancer Immunotherapy Market Overview And Prospects – Includes Cancer Immunotherapy Market Share

Read More

How Will The Biosimilar Interleukins Market Grow In 2022?

Read More

Latest Cancer Clinical Decision Tools Market Growth Study 2022-2026 By The Business Research Company

Read More

Latest Digestive Health Supplements Market Growth Study 2022-2026 By The Business Research Company

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the nucleic acid based gene therapy market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the radiopharmaceuticals market research report 2022 with industry size, share, segments and market growth

Read More

Electrical Safety Personal Protective Equipment Global Market Report 2025 – By Product Type (Head Protection, Eye And Face Protection, Hearing Protection, Protective Footwear, Hand Protection, Arc Rated Clothing), By Application (Shock Hazard, Arc Flash Hazard), By End-User (Electrical, Automotive, Oil and Gas, Machinery, Construction, Mining, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Office And Factory Buildings Global Market Report 2025 – By Type (Residential, Non-residential ), By Construction Type (New Construction, Renovation ), By Application (Owned, Rental), By End User (Private, Public) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Food Colorants Global Market Report 2025 – By Type (Natural, Synthetic), By Source (Plant Derived Pigments, Mineral), By Solubility (Dye, Lake), By Form (Powder, Liquid), By Application (Beverages, Dairy And Frozen products, Bakery, Meat, Poultry, and Seafood, Confectionery, Sauces and Condiments, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Automotive Electric Vacuum Pump Global Market Report 2025 – By Product Type (Diaphragm Type, Leaf Type, Swing Piston Type), By Propulsion Type (Electric Vehicle (EV), Internal Combustion Engine (ICE)), By Vehicle Type (Passenger Vehicles, Light Commercial Vehicles, Heavy Commercial Vehicles ), By Sales Channel (Original Equipment Manufacturer (OEM), Aftermarket) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Tile Abrasion Testing Global Market Report 2025 – By Type (Deep Abrasion Tester, Scratch Resistance Tester, Stain Resistance Tester, Slip Resistance Tester), By Test Type (Taber Abrasion Test, Mohs Hardness Test, Bohme Abrasion Test), By Application (Residential, Commercial, Industrial) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Vehicle Radar Test System Global Market Report 2025 – By Components (Vector Signal Transceiver (VST), Variable Delay Generator (VDG), PXI Controller, Antennae), By Vehicle Type (Passenger Cars, Commercial Vehicle), By Frequency Band (X-Band, K-Band, Other Frequency Brands), By Application (Research And Development, Radar Module Manufacturing, Vehicle Manufacturing, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Prescriptive Analytics Global Market Report 2025 – By Solution (Software, Services), By Deployment Mode (Cloud, On-Premises), By Organization Size (Large Enterprises, Small And Medium-Sized Enterprises (SME’s)), By Application Type (Risk Management, Operations Management, Revenue Management, Network Management, Supply Chain Management, Workforce Management), By Industry Vertical (Manufacturing, Energy And Utilities, Media And Entertainment, Transportation And Logistics, Healthcare And Life Sciences, Retail And Consumer Goods, Banking Financial Services And Insurance (BFSI), Information Technology And Telecommunications, Other Industry Verticals) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Acute Intermittent Porphyria market?

Acute intermittent porphyria (AIP) is a rare genetic disorder that affects the production of heme, a vital component of hemoglobin in the blood. AIP is characterized by intermittent attacks of severe abdominal pain, gastrointestinal disturbances, and neurological symptoms, including muscle weakness, seizures, and mental changes such as anxiety, confusion, or hallucinations. For further insights on the Acute Intermittent Porphyria market, request a sample here

How will the Acute Intermittent Porphyria market drivers and restraints affect the market dynamics? What forces will shape the Acute Intermittent Porphyria industry going forward?

The Acute Intermittent Porphyria market major growth driver - Impact Of Rising Metabolic Disorders On The Growth Of The Acute Intermittent Porphyria Market. For further insights on the Acute Intermittent Porphyria market, request a sample here

What is the forecast market size or the forecast market value of the Acute Intermittent Porphyria market?

The Acute Intermittent Porphyria market size has grown strongly in recent years. The acute intermittent porphyria market size has grown strongly in recent years. It will grow from $4.37 $ billion in 2024 to $4.66 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising healthcare expenditure, growth in biopharmaceuticals market, rising prevalence of genetic disorders, expansion of telemedicine services, and growing focus on early detection. The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $5.96 $ billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing incidence of acute intermittent porphyria, growing awareness of rare diseases, supportive government policies, growing patient advocacy, and expansion of genetic testing services. Major trends in the forecast period include advancements in diagnostic techniques, development of novel therapeutic options, investment in research and development, collaborations between pharma companies, and technological innovations in treatment. For further insights on the Acute Intermittent Porphyria market, request a sample here

How is the Acute Intermittent Porphyria market segmented?

The acute intermittent porphyriamarket covered in this report is segmented –
1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis
2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments
3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers
Subsegments:
1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test
2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test
3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test
4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test
5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays. For further insights on the Acute Intermittent Porphyria market, request a sample here

Which region has the largest share of the Acute Intermittent Porphyria market? What are the other regions covered in the report?

North America was the largest region in the acute intermittent porphyria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Acute Intermittent Porphyria market, request a sample here.

Who are the major players in the Acute Intermittent Porphyria market?

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc. . For further insights on the Acute Intermittent Porphyria market, request a sample here.

What are the key trends in the Acute Intermittent Porphyria market?

Major trends in the Acute Intermittent Porphyria market include Innovations In Acute Intermittent Porphyria Management. For further insights on the Acute Intermittent Porphyria market, request a sample here.

What are the major opportunities in the Acute Intermittent Porphyria market? What are the strategies for the Acute Intermittent Porphyria market?

For detailed insights on the major opportunities and strategies in the Acute Intermittent Porphyria market, request a sample here.

How does the Acute Intermittent Porphyria market relate to the overall economy and other similar markets?

For detailed insights on Acute Intermittent Porphyria's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Acute Intermittent Porphyria industry?

For detailed insights on the mergers and acquisitions in the Acute Intermittent Porphyria industry, request a sample here.

What are the key dynamics influencing the Acute Intermittent Porphyria market growth? SWOT analysis of the Acute Intermittent Porphyria market.

For detailed insights on the key dynamics influencing the Acute Intermittent Porphyria market growth and SWOT analysis of the Acute Intermittent Porphyria industry, request a sample here.